Gaviscon Infant

Helps to prevent gastric reflux and regurgitation. Oral powder suspension Suitable for children ages 1 to 2

Available in: 30s

Product Description

Gaviscon Infant helps prevents reflux, where the stomach contents seep back up the oesophagus (food pipe). Gaviscon Infant has two main ingredients sodium alginate and magnesium alginate which form a gel in the stomach when they come into contact with stomach acid and thickens stomach contents. This helps prevent reflux

UK/G-OTC/0318/0033f

Each unit dose sachet of 0.65g powder contains 225mg sodium alginate & 87.5mg magnesium alginate

Do not store above 30°C.

For infants aged 1 to 2 years. Not to be used in premature infants or infants under one year except under medical supervision. Treatment should not be administered more than six times in any 24 hour period. Not suitable for children over 2 years of age, adults or the elderly. Mix immediately before use as directed: Infants under 4.5 kg (10lb) – one sachet should be used; Infants over 4.5kg (10lb) – two sachets should be used. Bottle fed infants: • Mix each sachet into 115 ml (4 fl oz) of feed in the bottle. • Shake well • Feed as normal. Breast fed infants and other infants up to 2 years: • Mix each sachet with 5 ml (1 teaspoon) of cooled boiled water until a smooth paste is formed; • Add another 10 ml (2 teaspoons) of cooled boiled water and mix; • For breast fed infants give Gaviscon Infant part way through each feed or meal using a spoon or feeding bottle. • For all other infants give Gaviscon Infant at the end of each meal using a spoon, or feeding bottle.

A medical review of the patient's condition should be undertaken seven days after initiating treatment or before if symptoms worsen. Significant or sustained changes in bowel habit or stool consistency e.g. diarrhoea or constipation, should be investigated. Follow dosage instructions exactly to avoid an excessive amount of product per feed and the possible risk of hypernatraemia. Not to be used when treating infants with known or suspected impairment of renal function as the sodium content (approximately 21 mg or 0.92 mmol per dose) may add to the risk of hypernatraemia. Hypernatraemia should be treated with oral fluids and monitoring of the infant's electrolytes. Severe cases should be treated by the cautious use of hypo-osmotic solutions.